Cell line · CVCL_1619
Papers39
1 to 20 of 39
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting SMC3 deacetylation synergizes with XPO1 inhibition to reprogram the epigenetic landscape and suppress NPM1-mutated acute myeloid leukemia. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development of CAR T Cells Targeting a Surface RNA-Binding Protein for the Treatment of Acute Leukemias. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cysteine-reactive covalent chloro-N-acetamide ligands induce ferroptosis mediated cell death. | EMBO Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway | Res Sq | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. | Mol Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). | Blood Cancer J | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18. | Cell Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| An alternative NURF complex sustains acute myeloid leukemia by regulating the accessibility of insulator regions. | EMBO J | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting human mitochondrial NAD(P)+-dependent malic enzyme (ME2) impairs energy metabolism and redox state and exhibits antileukemic activity in acute myeloid leukemia. | Cell Oncol (Dordr) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. | Blood Cancer J | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. | Int J Mol Sci | 2023 | Cellosaurus cites it | PubMed | |
| ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1619/papers